IntelliCell's fat-derived stem cells termed "technological breakthrough" in Forbes

IntelliCell BioSciences (OTCBB:SVFC) has made a technological breakthrough into the regenerative medicine field, according to blog entry in Forbes.
The company, through its proprietary technology, processes stromal vascular fraction (SVF) stem cells, derived from one's own body fat.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for anti-aging effects, as well as for the treatment of more serious conditions like arthritis, congestive heart failure, gum recession, and wound healing.
IntelliCell's SVF cells can be used to treat certain conditions, or rejuvinate damaged tissue and cell function. The company, which under the FDA is authorized to commercially sell its SVF cells, has also applied for a patent on its use of ultrasonic cavitations to break up fat cells, which increases the number of SVF stem cells that can be extracted from just two ounces of fat to between 500 million and 1.4 billion, Forbes said.
The company's technique takes approximately 30 minutes, costs less than other stem cell extraction products, and the stem cells can be returned to a patient’s doctor in the same day.
"It is very apparent that a person’s fat cells are the best source of stem cells, which are stored inactively in one’s fat tissues, for use in the fast growing field of regenerative medicine," IntelliCell CEO, Dr. Steven Victor told Forbes.
Forbes noted that IntelliCell's technology can produce an average of 10 times the number of stem cell-containing SVF cells as traditional methods, which require the use of enzymes, according to a study of the company's technology by a unit of Merck AG.
Indeed, these fat stem cells have similar potential to embryonic stem cells in their pluripotency, and are from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In the aesthetic world, the use of autologous adipose, or fat, stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has also treated more than 100 patients this year alone, Forbes said, including the wife and daughter of MAZ Capital Advisors' president, and IntelliCell shareholder, Walter Schenker. Each underwent a successful treatment at an IntelliCell lab for knee ailments, Forbes cited.
IntelliCell, whose shares on the OTC were trading at $3.95 on Monday, has established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into licensing agreements for centers in Houston and Palm Beach.